RedudionjofLDL-cholesterol through the: use;q^ mprtality and n(i6rb)<3ity caused by GO ro disease (GHD), Nevertheless, GHD remains the leading caijse of: death fbrnnen and vfi?3men in the United Stat^, OneireasQfi for the persistence of CHD may be the tacfebf:therapies'that;)riqrease;:(HE)L-chQieste^ ?lt'is:wiBll'established:that.,l-iDL-d'conGertti?!tion is-a'^ stripng,ihdeipendentjnver^ely^^^m^ Because of data Indicating that a 1 mg/dl increase in HDL.-C decreases CHD risk;by ^^^^ therapiesiihdt'yyili'.ieffe'diWjy.iele^ <3ri6 class''ibif'Comfiounds::that;'may have.great;"""""""" therapeutic potential are PHARd agonists, which in non'human primates can elevate HDLrG by 43-79% and apo/V-1, themajor apolipoprotein of HiDL, by 43i%. Irt this applicatiprv, j prpposetpdeflne;the mechanisms by which PPARftagtjhlstsiriGiuceHpL-G elevation in non-liymari primates, twill deteriTiine whether PPARS agonists increase HDL-G by: 1) altering HDL production or catabolism;2) changing the activity of plasma ITpasiis, lipid transfer proteins, and LGAT;3) mpdolating themRNA and protein expression of genes involved in HDL metabolism. In addition, I pnoppse to determine whether PPAR6 agonists elevate HDL-C in monkeys that have Ibeen treated with antisense oligonudeptides that suppress hepatic expression of ATP binding cass|0e,trarispdrter A;^ .iCAS'C^ deN^loprhisfit of rnbre-potent PPAR6 agbnlsts or other therapiesthateffeetiveiy increase HbL-C. which in turn could prevent CHD in hundreds of thousands pf people each year in the Onlted Statisss and around the world. Scientific data indicates that inGreasing HDL choiasterol may decree cause of death for men arid women in the United States. We propose to determine the mechanisms by which a new class of drugs, known as RPAR;delta agonists, increase HDL-Ghdlesterolin monkeys. Because of the high cjegr^ of similality between the bodies of studies yillproyideinsighlsf6i'the development of therapieis that could increase HDL and prevent the deaths of iiuhdreds of thousands of;people each year from heart disease.
Scientific data indicates that increasing HDL cholesterol may decrease the risk of heart disease, the leading cause of death for men and women in the United States. We propose to determine the mechanisms by which a new class of drugs, known as PPAR delta agonists, increase HDL-cholesterol in monkeys. Because of the high degree of similarity between the bodies of humans and monkeys, we feel confidant that these studies will provide insights for the development of therapies that could increase HDL and prevent the deaths of hundreds of thousands of people each year from heart disease.
|Ouimet, Mireille; Hennessy, Elizabeth J; van Solingen, Coen et al. (2016) miRNA Targeting of Oxysterol-Binding Protein-Like 6 Regulates Cholesterol Trafficking and Efflux. Arterioscler Thromb Vasc Biol 36:942-951|
|Okla, Meshail; Ha, Jung-Heun; Temel, Ryan E et al. (2015) BMP7 drives human adipogenic stem cells into metabolically active beige adipocytes. Lipids 50:111-20|
|Medina, Marisa W; Bauzon, Frederick; Naidoo, Devesh et al. (2014) Transmembrane protein 55B is a novel regulator of cellular cholesterol metabolism. Arterioscler Thromb Vasc Biol 34:1917-23|
|Chung, Soonkyu; Cuffe, Helen; Marshall, Stephanie M et al. (2014) Dietary cholesterol promotes adipocyte hypertrophy and adipose tissue inflammation in visceral, but not in subcutaneous, fat in monkeys. Arterioscler Thromb Vasc Biol 34:1880-7|
|Hong, Cynthia; Marshall, Stephanie M; McDaniel, Allison L et al. (2014) The LXR-Idol axis differentially regulates plasma LDL levels in primates and mice. Cell Metab 20:910-8|
|Beason, David P; Hsu, Jason E; Marshall, Stephanie M et al. (2013) Hypercholesterolemia increases supraspinatus tendon stiffness and elastic modulus across multiple species. J Shoulder Elbow Surg 22:681-6|
|Owens 3rd, A Phillip; Passam, Freda H; Antoniak, Silvio et al. (2012) Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest 122:558-68|
|Rayner, Katey J; Sheedy, Frederick J; Esau, Christine C et al. (2011) Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 121:2921-31|
|Rayner, Katey J; Esau, Christine C; Hussain, Farah N et al. (2011) Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478:404-7|
|Temel, Ryan-E; Brown, J-Mark (2010) A new framework for reverse cholesterol transport: non-biliary contributions to reverse cholesterol transport. World J Gastroenterol 16:5946-52|